The first major mergers & acquisitions (M&A) deal was announced Thursday morning when Bristol-Myers Squibb (BMY) announced its intent to buy Celgene (CELG) for $74 billion.

TheStreet's Martin Baccardax reported on the deal, which was made public before the market opened Thursday.

According to Bristol-Myers, Celgene investors will receive a Bristol-Myers share and $50 for each Celgene holding that they have. Investors would also get a special rights issue that will pay off if the merged group meets certain business targets.

The deal values Celgene at $102.43 each, the companies said, a 53.7% premium to Wednesday's closing price. The combined group -- which will be 69% owned by Bristol-Myers -- would have a portfolio with nine drugs that generate more than $1 billion in sales, the companies said.

Cramer said that he was worried about the deal.

"Celgene has made so many bad acquisitions," Cramer said. "Bristol-Myers has made so many bad acquisitions. I mean, maybe this is the one [good one]."

More from Video

What's Behind the Retail Sector's Fall From Grace? NYSE Trader Weighs in

What's Behind the Retail Sector's Fall From Grace? NYSE Trader Weighs in

Jim Cramer Likes Secular Growers

Jim Cramer Likes Secular Growers

In the Shadow of Bankruptcy: Distressed Investing Opportunity

In the Shadow of Bankruptcy: Distressed Investing Opportunity

$1,320 Gold May Be In The Cards

$1,320 Gold May Be In The Cards

CES 2019: The Future Is Here and it's a Walking Car

CES 2019: The Future Is Here and it's a Walking Car